CRC Research Update — July 30, 2026
Today's colorectal cancer research highlights
her2
A collection of 32 issues
Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease
Skip to content
The CRC Digest
▸ TREATMENT
Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease
Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology)
This content is
CRC Research Update — July 28, 2026
Today's colorectal cancer research highlights
Spatial Tumor Variation May Explain HER2 Testing Discrepancies
Skip to content
The CRC Digest
◇ RESEARCH
Spatial Tumor Variation May Explain HER2 Testing Discrepancies
A retrospective analysis of 1,343 colorectal cancer cases found that spatial intratumoral heterogeneity in HER2 overexpression contributes to discordance between immunohistochemistry/FISH and next-generation sequencing, with implications for HER2-targeted therapy selection. (Virchows Arch)
This
CRC Research Update — July 10, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 25, 2026
Today's colorectal cancer research highlights
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes
Skip to content
The CRC Digest
▸ TREATMENT
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open
An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
Skip to content
The CRC Digest
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open)
This content is informational only and does not constitute medical advice.
Always consult